All lobbying filings

RK Strategies, Inc.

RK Strategies, Inc. filed a Q3 report for Recce Pharmaceuticals Ltd. on October 20, 2026, reporting $20,000 in lobbying income.

Lobbying for Recce Pharmaceuticals Ltd. · Pharmaceutical Company - Anti-infectives

As filed: RK STRATEGIES, INC. for RECCE PHARMACEUTICALS LTD.

All filings by RK Strategies, Inc. · Everything Recce Pharmaceuticals Ltd. has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Income

$20,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 5

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 3

Veterans

General wound care issues

Health Issues

General healthcare/wound care issues Pandemic and All Hazards Preparedness Act Reauthorization Appropriations Issues

Defense

General biodefense/wound care issues Pandemic and All Hazards Preparedness Act Reauthorization Other Appropriations Issues Related to Wound Care/Biodefense

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.